Paris, February 27th, 2015 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful private placement of 713,380 new ordinary shares to institutional investors of Cardio3 Biosciences for an amount of €32m. Bryan, Garnier & Co acted as Placement Agent alongside UBS Investment Bank and Petercam.
Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of cell therapies, today announced it has raised approximately €32 million through a private placement of ordinary shares to investors in the United States and Europe.
Cardio3 BioSciences has placed 713,380 new shares to qualified institutional investors in the United States and Europe at a price of €44.50 per share, with no discount to the previous day closing price and a 4% premium to the last 30 day average price. The placed shares represent 10% of the current number of outstanding shares, bringing the total number of shares outstanding after the issue to 7,847,187. The new shares are expected to be admitted to trading on Euronext Brussels and Paris following their issuance, which is expected to take place on Tuesday, 3 March 2015. 40% of the placement was made on the US market, through à 144A placement.
The proceeds from the private placement will be used by Cardio3
- Further develop its newly acquired CAR-T cell technology
- Strengthen the leadership of C-Cure® for the treatment
of congestive heart failure, and;
- For general corporate purposes.
For the past 18 years, Bryan,
Garnier & Co has been one of the leading European placement agents for
growth capital, with more than 50 transactions led, including late stage
venture, development stage financings, IPOs, follow-on offerings as well as PIPEs.
In 2014, Bryan, Garnier & Co led the €100m private placement for Mérieux
NutriSciences, the largest European growth equity financing in the healthcare
sector. Recent growth financing transactions led by Bryan, Garnier & Co
include the €37m IPO of Bone Therapeutics on Euronext, the £100m IPO of Quantum
Pharma on the LSE, the $133m IPO of DBV Technologies on Nasdaq and the €25m
private placement for the software company Jahia.
Jean-Christophe Renondin, Managing Director Healthcare, stated: “The success of the Book Building placement of Cardio3 BioSciences reiterates Bryan Garnier international health care franchise and the strong commitment of our teams to support growth innovative companies. Bryan Garnier is very proud of supporting the Cardio3 BioSciences team in this significant value-creation step.”
Cédric Moreau, Director ECM Healthcare, added: “The global offering was strongly oversubscribed in both Europe and in the
US. Once again, Bryan Garnier played a key role in a cross-border ECM Healthcare
transaction. We expect this success to confirm positive investors’ sentiment on
the European Healthcare industry where a number of key catalysts are expected this
For more information, please contact:
Partner – Healthcare Corporate Finance
firstname.lastname@example.org | + 33 156687522
Managing Director – Healthcare Corporate Finance
email@example.com | + 33 156687504
Director – Healthcare Equity Capital Markets
firstname.lastname@example.org | + 33 156687565
Director – Equity Capital Markets
email@example.com | + 33 156687530
About Cardio3 Biosciences (www.c3bs.com)
Cardio3 BioSciences is a leading biotechnology company focused on the discovery and development of cell therapies for the treatment of unmet medical needs in cardiology and oncology. Founded in 2007 and based in the Walloon region of Belgium, Cardio3 BioSciences leverages research collaborations in the USA and in Europe with the Mayo Clinic (MN, USA), and Dartmouth College (NH, USA). The Company’s lead product candidate in cardiology is C-Cure®, an autologous stem cell therapeutic using adult guided stem cells for the condition of congestive heart failure. The Company’s lead product candidate in oncology is CM-CS1, an autologous CAR T-Cell product candidate using NKG2D, a Natural Killer (NK) cell receptor designed to target ligands present on most tumor types, including hematologic cancers and solid tumors. Cardio3 BioSciences is also developing a portfolio of medical devices for enhancing the delivery of bio therapeutic agents into the myocardium (C-Cathez®) and for cardiac surgery involving mitral valve defects. Cardio3 BioSciences’ shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.
About Bryan, Garnier & Co (www.bryangarnier.com)
Bryan, Garnier & Co is an international growth-focused independent investment bank with operations in London, Paris, Geneva, New York and New Delhi. Since 1996, Bryan, Garnier & Co has dealt with over 300 corporate clients. The firm employs 120 people and provides equity research, sales & trading, private and public capital raising and M&A services to growth companies and their investors, with a focus on the TMT, Healthcare, Renewable Energies & Environment, Specialty Retail and Business Services industry sectors. In 2013, Bryan, Garnier & Co received the Most Productive European Broker Award by Financial Times / Starmine. Bryan, Garnier & Co is a fully registered broker dealer authorized by the FCA in Europe and by the FINRA in the USA, and is a member of the London Stock Exchange, a member of NYSE Euronext and a listing sponsor on Alternext.